Bone Biologics Co. (NASDAQ:BBLG) Short Interest Up 48.4% in October

Bone Biologics Co. (NASDAQ:BBLG) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 72,100 shares, a growth of 48.4% from the October 15th total of 48,600 shares. Based on an average daily volume of 3,010,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 13.8% of the company’s shares are short sold.

Bone Biologics Stock Down 7.8 %

Shares of BBLG stock opened at $1.19 on Friday. The company has a 50 day moving average price of $1.64 and a 200 day moving average price of $1.59. Bone Biologics has a one year low of $0.80 and a one year high of $10.56.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.